AU Patent

AU2018203098B2 — Compositions and methods for inhibiting expression of the alas1 gene

Assigned to Icahn School of Medicine at Mount Sinai · Expires 2020-05-14 · 6y expired

What this patent protects

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALASI gene, and methods 5 of using such dsRNA compositions to alter (e.g., inhibit) expression of ALASI. W:\NRPortbl\GHMatters\MICHELES\10234591_1.docx 3/05/18

USPTO Abstract

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALASI gene, and methods 5 of using such dsRNA compositions to alter (e.g., inhibit) expression of ALASI. W:\NRPortbl\GHMatters\MICHELES\10234591_1.docx 3/05/18

Drugs covered by this patent

Patent Metadata

Patent number
AU2018203098B2
Jurisdiction
AU
Classification
—
Expires
2020-05-14
Drug substance claim
No
Drug product claim
No
Assignee
Icahn School of Medicine at Mount Sinai
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.